Invest-NL invests € 6 million in Xeltis

The fundraise has been backed by a syndicate of current and new investors, including Grand Pharma, DaVita Venture Group, EQT Life Sciences, Invest-NL and other international investors.

Xeltis' key objective is to bring ground-breaking implants to the market that function longer and better than current solutions. Clinical studies are currently underway in several indications, of which aXess - the vascular implant for patients with kidney failure - is at the forefront. More than 1.7 million Dutch people have chronic kidney damage and therefore have an increased risk of kidney failure and cardiovascular disease. For the group of patients who need dialysis treatment, the aXess may offer a better dialysis implant that will significantly improve the quality of life of these patients.

This fundraising round will enable Xeltis to progress its key clinical programs into pivotal trials, as it aims to give patients around the world access to the world’s most advanced restorative cardiovascular devices.

Eliane Schutte, CEO of Xeltis. “Securing this financing is an important milestone for Xeltis. It will enable us to further validate our technology in large-scale clinical trials, transforming cardiovascular surgery through better implants and better clinical outcomes. We are proud to have attracted such high-profile investors to our company and look forward to leveraging their respective insights – from clinical expertise to the product development lifecycle – as we continue on the next phase of growth.”

For Invest-NL, the investment in Xeltis ties in well with its strategic focus on keeping healthcare in the Netherlands accessible and affordable. Xeltis’ highly innovative products not only contribute to an improvement in both the quality of treatment and the quality of life for patients. Significant savings in healthcare costs in the Netherlands are also expected due to the prevention of common complications.

“In order to determine the social benefits of our investment in Xeltis, Invest-NL has studied how much healthcare costs the innovation may prevent on the Dutch market and who will benefit from the savings: patient, healthcare provider or healthcare insurer. In addition, we also calculated how many healthy years of life the innovation will yield. By looking at our investments in healthcare from an impact perspective, we take financing healthcare innovations to the next level,” says Rinke Zonneveld, CEO of Invest-NL.

Go to press release